Semaglutide and tirzepatide shortages have largely resolved in 2025, but demand remains high
Last reviewed: June 29, 2026 Last updated: June 29, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations
Onpattro (patisiran, siRNA) IV legacy option
Researchers who lost their trusted supplier or who have been frustrated by payment friction, shipping delays, access restrictions, or fee surcharges at their current vendor are evaluating every option with more scrutiny than ever before
Novo Nordisk owns the patent for semaglutide, meaning that compound versions of the drug are not allowed
Tirzepatide for managing overweight and obesity (TA1026) NICE